Robert Ford on CGM reimbursement
From Abbott Laboratories ($ABT) Q1 2026 Earnings Call · · Castify Earnings Call
“I expect proposed language of that coming soon. I can't tell you the exact month, Larry, and I'm not going to try and forecast what it is, when it is, but I know it's going to happen. And I know that it's going to add close to 10 million people that don't have coverage now that now will be able to have coverage. And obviously going to accelerate commercial coverage, too. So, I think that's a catalyst that's on the horizon here for us.”
On , Robert Ford, Chairman, President & CEO at Abbott Laboratories, spoke about CGM reimbursement during Abbott Laboratories ($ABT) Q1 2026 Earnings Call on Castify Earnings Call.
About Robert Ford
On Abbott's first-quarter 2026 earnings call, Robert Ford stated he remains "very confident" in an acceleration of growth in the second half of the year, saying the company knows "what the drivers are" and is "laser focused" on execution. Ford described the integration of Exact Sciences as going "very well" and expressed optimism about the continuous glucose monitoring (CGM) market, estimating that 70 to 80 million people globally should be using CGMs compared to a current market of around 10 to 12 million. He also said he expects proposed language for CMS type 2 non-insulin coverage "coming soon," which he said would add coverage for close to 10 million people. Regarding Abbott's nutrition business, Ford said he would not make a long-term strategic decision based on near-term challenges and that his focus is on returning the business to its prior growth rate. He described the company as "very diversified" and noted that while it would be "great" for every business to beat expectations, that does not always happen. Ford also said the electrophysiology market is expected to grow in the "mid to high teens" and that Abbott is "shooting to do better than that."